Stellus Capital shows poor earnings, weak dividend coverage, high non-accruals and limited growth with declining NAV. Learn ...
Received FDA IND clearance to evaluate CDI-988 as both norovirus preventive and treatmentExpects to initiate CDI-988 Phase 1b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback